Immix Biopharma Announces Closing of $125 Million Underwritten Offering of Common Stock
Globe Newswire•30/09/2026•17:15 ET
1
Key Highlights
- ➤Immix Biopharma (IMMX) closed $125 million underwritten common-stock offering.
- ➤11,363,637 shares sold at $11.00 per share.
- ➤Net proceeds totaled approximately $117.1 million after offering expenses.
- ➤Proceeds will fund NXC-201 development, working capital, and general corporate purposes.
– Financing includes leading U.S. biotechnology institutional investors and mutual funds –
LOS ANGELES, CA, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “we” or “us” or “IMMX”), a global leader in relapsed/refractory AL Amyloidosis, today announced the closing of its previously announced underwritten registered offering of 11,363,637 shares of its common stock at a public offering price of $11.00 per share. The net proceeds to Immix from the offering, after deducting the underwriting discounts, commissions and other offering expenses, were approximately $117.1 million.
Get started
Create a free account to read the full story.